Kara Cardinale serves as principal of Kasper Cardinale Consulting, LLC, an independent health policy consultancy that provides strategic advice and analysis to clients on regulatory and legislative actions impacting the health care industry. She currently serves as an external senior advisor and consultant to the District Policy Group, providing the team and their clients with Medicare coverage and payment policy expertise and support as well as insight and analysis regarding the federal budget, entitlement programs, and the overall health care regulatory and reimbursement environment. Kara brings extensive knowledge and experience with respect to the federal health care policymaking process and served within the executive branch under both Republican and Democratic administrations, providing her a unique perspective with respect to federal health care policy decision making.
Previously, Kara served as a Medicare program examiner at the White House Office of Management and Budget (OMB) during enactment of the Affordable Care Act of 2010 (ACA) and implementation of the Medicare Modernization Act of 2003 (MMA), which established the Medicare Part D prescription drug benefit. In particular, Kara served as the lead OMB analyst on Medicare Part D and other policy issues related to the biopharmaceutical industry, including Medicare Part B drugs, biosimilars, and Medicare Advantage. In this capacity, she assisted White House officials in negotiations with Congress and stakeholders over the ACA and other legislation, analyzed regulations and guidance promulgated by the Centers for Medicare and Medicaid Services (CMS) on Part D and Medicare Advantage including the annual Call Letter and Rate Announcement, crafted policies for consideration to improve the Part D program, and developed public communications documents on the drug benefit, among other work. Kara also led review of CMS regulations covering Medicare Fee-For-Service providers, including outpatient hospitals (OPPS), ambulatory surgical centers (ASCs), End-Stage Renal Disease (ESRD) facilities, and skilled nursing facilities (SNFs).
Early in her career, Kara was a reporter for “The Pink Sheet,” a trade publication covering the biopharmaceutical industry where she focused primarily on Food and Drug Administration regulatory policy. She also interned at the FDA and the Texas Health and Human Services Commission assessing policies impacting the State’s Medicaid and State Children’s Health Insurance Program.
A native of Knoxville, Tennessee, Kara earned her Bachelor of Arts in philosophy from Haverford College and a Master’s of Public Policy from the University of Texas at Austin. Kara lives with her husband and two young children in North Carolina.